FDA Drug Listing Versus Establishment Registration: Roles And Responsibilities

FDA Drug Listing Listing with FDA of drugs in commercial distribution by covered registered drug establishments. The term is often conflated with establishment registration, but the two are distinct regulatory obligations that work together to identify where a product is made and what products a registrant markets.

Understanding the difference is practical for retailers, manufacturers and logistics operators because each obligation answers a different question: registration names the place; listing names the products. Both are part of the FDA’s framework to support inspections, recalls and import enforcement.

What Establishment Registration Covers

Establishment registration creates a record of physical locations connected with drug activity. Registration typically includes the facility name, address and the types of operations performed (manufacture, repackaging, relabeling, etc.). It tells FDA where an inspection can occur and who is responsible at the facility.

What Drug Listing Covers

Drug listing catalogs the products that a registrant markets. It identifies each marketed dosage form, strength and package configuration and links those products back to the registrant and the establishments that produce them. Listing is the product-level counterpart to the site-level registration.

How The Two Requirements Interact

Registration and listing are complementary:

• Registration: Answers "Where is the product made?" — records facility names and addresses for inspection and enforcement.
• Listing: Answers "What is being marketed?" — details each product and its marketed packages tied to a registrant.
• Use Together: For recall targeting, regulators use both records to determine which facilities made the affected lot and which product configurations were distributed.

Who Must Do Each

Roles differ by activity:

• Mandatory Registrants: Manufacturers, repackers, relabelers and certain other establishments performing operations described in FDA regulations must register their establishments.
• Mandatory Listers: Those registrants who place drug products into commercial distribution must list the marketed products.
• Distributors/Wholesalers: Generally do not register or list unless they perform manufacturing activities; they must, however, verify that their suppliers are registered and listed.

Practical Compliance Implications For Retailers

Retailers seldom hold registration or listing obligations, but must be aware of the downstream consequences:

• Inspection Targeting: FDA uses registration records to select inspection sites that produce drugs listed for the market; retailers who source from unregistered facilities risk interrupted supply if FDA takes enforcement action.
• Import Refusals: Imported drugs that originate from unregistered or unlisted establishments may be refused entry; retailers importing private-label goods must ensure registration/listing compliance upstream.
• Recall Clarity: When a recall occurs, listing records determine which package sizes and labelers are affected — retailers need that granularity to remove impacted SKUs quickly.

Example Scenario

A retailer contracts a private-label manufacturer to produce an OTC analgesic. The manufacturer registers its facility (establishment registration) and lists the analgesic with relevant package sizes (drug listing). If the retailer later changes the product’s packaging or label, the manufacturer must update the FDA listing to reflect the new package configuration; if the listing isn’t updated and a recall occurs, the retailer may struggle to demonstrate whether its stock was affected.

In short, the FDA Drug Listing records the products marketed by registered establishments while establishment registration identifies the physical sites. Both are required when a company manufactures or markets drugs; retailers and logistics partners should verify both records for suppliers to reduce regulatory and operational risk.